Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC

Inclusion Criteria: * 1\. Voluntary signing of a written ICF. * 2\. Age at enrollment: 18-75 years; both sexes are eligible. * 3\. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 or 1. * 4\. Expected survival: ≥3 months. * 5\. Histologically or cytologically confirmed stage III NSCLC (classified according to the International Union Against Cancer and the American Joint Committee on Cancer's 9th edition of the lung cancer TNM staging system). * 6\. Definitively determined as unresectable after MDT discussion. * 7\. The primary driver genes must not harbor sensitive mutations (including EGFR (exon 19 deletion, exon 21 L858R point mutation, exon 20 insertion, etc.), ALK fusion, ROS1 fusion, MET exon 14 skipping mutation, HER2 exon 20 mutation, BRAF V600E mutation, RET fusion, NTRK fusion). For non-squamous NSCLC, a prior tissue-based common genetic testing report must be provided; otherwise, tumor tissue samples (archived or fresh, primary or metastatic) must be collected prior to enrollment for genetic mutation status assessment (at a local laboratory or central laboratory). For squamous NSCLC subjects with a smoking history or current smoking status, if the prior primary driver gene mutation status is unknown, no corresponding testing is required prior to enrollment, and the status shall be considered negative. * 8\. No prior systemic antitumor therapy or chest radiotherapy for NSCLC. * 9\. At least one measurable lesion according to RECIST v1.1, and suc…